Drug Type Small molecule drug |
Synonyms Bradanicline (USAN/INN), Bradanicline Hydrochloride, ATA 101 + [3] |
Target |
Mechanism α7 receptor agonists(Neuronal acetylcholine receptor protein alpha-7 subunit agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization Targacept, Inc. ![]() |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23N3O2 |
InChIKeyOXKRFEWMSWPKKV-GHTZIAJQSA-N |
CAS Registry639489-84-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10613 | Bradanicline | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory chronic cough | Phase 2 | US | Attenua, Inc.Startup | 05 Nov 2018 |
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | 01 May 2010 | |
Cognitive Dysfunction | Phase 2 | US | 01 Oct 2009 | |
Cognitive Dysfunction | Phase 2 | IN | 01 Oct 2009 | |
Schizophrenia | Phase 2 | US | 01 Oct 2009 | |
Schizophrenia | Phase 2 | IN | 01 Oct 2009 | |
Alzheimer Disease | Phase 1 | US | 01 Sep 2010 |